Over 60% Of Healthy Adults Have Pancreatic Pre-Cancerous Lesions, Research Suggests

New Study Explains Why Most Never Turn Deadly

Most people have never heard of pancreatic intraepithelial neoplasia, or PanINs, but a major new study suggests that many of us could be carrying them. In an earlier analysis of 30 donated pancreases, researchers found that more than 60% contained PanIN lesions. The surprising part? The vast majority never turn into full-blown cancer. Now, researchers have a stronger clue as to why.

A team of scientists at the University of Michigan and collaborating institutions compared the biological environment surrounding these precursor lesions, using healthy donor tissue, to that of full-blown pancreatic cancer. Lesion cells already show some cancer-like patterns of gene activity, but the tissue environment around them looks almost nothing like a tumor. That mismatch, the researchers argue, may be the very thing keeping most of these lesions dormant, and understanding it could be the key to catching pancreatic cancer before it becomes untreatable.

Rare Tissue, Rare Opportunity in Pancreatic Cancer Research

One of the biggest obstacles in pancreatic cancer research has always been access to healthy tissue. When a patient is diagnosed, the surrounding “normal” tissue is already disrupted by the nearby tumor’s influence. Getting a clean look at a pre-cancerous lesion in an otherwise healthy pancreas has historically been nearly impossible.

Researchers partnered with Gift of Life Michigan, an organ procurement organization, to obtain pancreases from more than 150 donors ranging in age from 20 to 70 years old. This gave them something rare: healthy pancreatic tissue containing naturally occurring pre-cancerous lesions, untouched by an active tumor.

From that donor pool, the team selected samples for a technique called spatial transcriptomics, which reads the genetic activity of cells while preserving information about exactly where in the tissue those cells sit. Researchers applied this to donor samples with pre-cancerous lesions, pancreatic cancer samples, and tissue adjacent to tumors, supplementing the analysis with a reference library of over 200,000 individual cells. All tissue was reviewed by board-certified pathologists before analysis began.

PanIN Cells Already Look Like Early Cancer, but Their Neighborhood Does Not

When the researchers compared the gene activity of pre-cancerous lesion cells to actual cancer cells, the lesion cells fell clearly on a spectrum pointing toward cancer. Signals tied to the KRAS gene, a mutation present in over 90% of pancreatic cancer cases and in nearly all pre-cancerous lesions, were already active. Inflammatory pathways showed early signs of increased activity, modestly elevated compared to normal tissue but far below levels seen in full-blown tumors.

But the tissue environment surrounding those lesions bore almost no resemblance to the landscape surrounding actual cancer. Around pre-cancerous lesions, an immune cell that produces antibodies, called a plasma cell, was abundant and clustered close by. In tumor samples, plasma cells were scattered and sparse, while a different immune cell, the macrophage, had moved in directly adjacent to the tumor cells. This geographic reshuffling of the immune landscape appears to be a hallmark of cancer, not precancer.

“Our findings describe unique features of the precancer microenvironment that are likely responsible for keeping precursor lesions from progressing to malignancy,” the authors write in Cancer Discovery.

The Support Cell That May Help Pancreatic Cancer Take Hold

Perhaps the most telling finding involves a type of structural support cell called a fibroblast. These cells are found throughout the body, helping to hold tissues together and regulate healing. In pancreatic tumors, a specific fibroblast population is known to help cancer grow and resist treatment.

Researchers identified a distinct fibroblast population, labeled Fibro2, that was heavily present in and around tumor tissue but essentially absent from pre-cancerous lesions. Fibro2 cells showed high activity of a gene called LEF1, part of a cellular communication pathway known as WNT signaling, previously linked to pancreatic cancer development. Surrounding pre-cancerous lesions, fibroblasts were plentiful but of a different kind, largely lacking the features associated with the cancer-driving Fibro2 type.

To test whether cancer cells were pushing fibroblasts toward this Fibro2 state, the team grew cancer tissue and fibroblasts together in a dish. When lab-grown miniature tumors were cultured with cancer-associated fibroblasts, LEF1 activity in those fibroblasts increased. When grown alongside normal fibroblasts from donor pancreases, LEF1 activity did not rise. Fibro2 consistently appeared near tumors and was consistently absent around non-malignant lesions across multiple independent datasets.

What This Means for Catching Pancreatic Cancer Early

Most pre-cancerous lesions in the pancreas exist in a kind of biological holding pattern: cells are abnormal, mutations are present, but the cancer never takes off. Without the fibroblast reprogramming, immune cell reshuffling, and activation of cancer-linked signaling pathways seen in tumors, that holding pattern appears to stay intact. The authors caution that PanINs themselves may not be a practical screening target, since they are both common and too small to detect noninvasively. If the real barrier to malignancy lies not in the lesion cells themselves but in whether the surrounding tissue has undergone a specific transformation, the path to earlier detection may run through that neighborhood, not just the cells at its center.

---

Disclaimer: This article is based on a single peer-reviewed study and is intended for general informational purposes only. It does not constitute medical advice. The findings reflect associations observed in a research setting and have not been translated into clinical screening tools or treatments. Consult a qualified healthcare provider with any questions about pancreatic health or cancer risk.

---